KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients-Reference-Cited by-同舟云学术

KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients

Published:2012-11-22 Issue:1 Volume:108 Page:115-120
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Basso M,Strippoli A,Orlandi A,Martini M,Calegari M A,Schinzari G,Di Salvatore M,Cenci T,Cassano A,Larocca L M,Barone C

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2012526.pdf

Reference26 articles.

1. Altaha R, Liang X, Yu JJ, Reed E (2004) Excision repair cross-complementing-group 1: gene expression and platinum resistance. Int J Mol Med 14: 959–970

2. Balin-Gauthier D, Delord JP, Pillaire MJ, Rochaix P, Hoffman JS, Bugat R, Cazaux C, Canal P, Allal BC (2008) Cetuximab potentiates oxaliplatin-induced cytotoxic effect through a defect in NER and DNA replication initiation. Br J Cancer 98: 120–128

3. Benhar M, Engelberger D, Levitzki A (2002) Cisplatin-induced activation of the EGFR receptor. Oncogene 21: 8723–8731

4. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P (2009) Fluorouracil, leucovorin and oxaliplatin with or without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27: 663–671

5. Breen D, Barlesi F (2008) The place of excision repair cross complementation 1 (ERCC-1) in surgically treated non-small cell lung cancer. Eur J Cardiothorax Surg 33: 805–811

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Impact of KRAS Mutational Status on Long-Term Survival following Liver Resection for Hilar Cholangiocarcinoma;Cancers;2022-09-08

2. Validation of Genetic Markers Associated with Survival in Colorectal Cancer Patients Treated with Oxaliplatin-Based Chemotherapy;Cancer Epidemiology Biomarkers & Prevention;2021-12-03

3. Predictive value of KRAS mutation and excision repair cross-complementing 1 (ERCC1) protein overexpression in patients with colorectal cancer administered FOLFOX regimen;Asian Journal of Surgery;2021-05

4. Discordance of KRAS Mutational Status between Primary Tumors and Liver Metastases in Colorectal Cancer: Impact on Long-Term Survival Following Radical Resection;Cancers;2021-04-29

5. Effective management of advanced colon cancer genotyping microsatellite stable/microsatellite instable-low with Kirsten rat sarcoma viral oncogene mutation using nivolumab plus ipilimumab combined with regorafenib and irinotecan: A case report;SAGE Open Medical Case Reports;2021-01